Form 4: Akebia Therapeutics SVP Michel Dahan Sells Shares to Cover Tax Obligations

Michel Dahan, SVP and Chief Operating Officer of Akebia Therapeutics, sold 10,744 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Michel Dahan, SVP and Chief Operating Officer of Akebia Therapeutics, sold 10,744 shares of common stock on February 27, 2024.
• The sale was executed at a price of $1.52 per share.
• The transaction was made automatically by the issuer to cover tax withholding obligations.
• This was in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
• Following the transaction, Dahan beneficially owns 715,593 shares of Akebia Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative outlook on the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates